Xihui Yu

Shantou, 515000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Phosphodiesterase 4 as a therapeutic target in Parkinson's disease recent advances.

Phosphodiesterase 4 as a therapeutic target in Parkinson's disease recent advances.

Journal: Experimental neurology

Published: October 25, 2025

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab.

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab.

Journal: Frontiers in pharmacology

Published: September 27, 2025

Drug-associated serotonin syndrome in elderly patients: a comprehensive disproportionality analysis based on the FAERS database.

Drug-associated serotonin syndrome in elderly patients: a comprehensive disproportionality analysis based on the FAERS database.

Journal: Frontiers in pharmacology

Published: September 06, 2025

Pharmacovigilance study on old drugs repurposed for rare diseases across different indications: the case of fenfluramine.

Pharmacovigilance study on old drugs repurposed for rare diseases across different indications: the case of fenfluramine.

Journal: Frontiers in pharmacology

Published: August 09, 2025

Roflupram Reduces 6-OHDA-Induced Cellular Damage in SH-SY5Y Cells by Inhibiting PDE4.

Roflupram Reduces 6-OHDA-Induced Cellular Damage in SH-SY5Y Cells by Inhibiting PDE4.

Journal: Journal of integrative neuroscience

Published: August 02, 2025

Inhibition of PDE4 Alleviates Endoplasmic Reticulum Stress and Neuronal Damage via Activation of Nrf2/HO-1 in Parkinson's Disease.

Inhibition of PDE4 Alleviates Endoplasmic Reticulum Stress and Neuronal Damage via Activation of Nrf2/HO-1 in Parkinson's Disease.

Journal: Molecular neurobiology

Published: July 30, 2025

Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS).

Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS).

Journal: Frontiers in pharmacology

Published: June 09, 2025

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS).

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS).

Journal: Frontiers in pharmacology

Published: May 06, 2025

The role of T cells in the treatment of Parkinson's disease.

The role of T cells in the treatment of Parkinson's disease.

Journal: PeerJ

Published: March 14, 2025

Effects of national volume-based procurement policy on the usage and expenditure of platinum antineoplastic drugs in China: an interrupted time series study.

Effects of national volume-based procurement policy on the usage and expenditure of platinum antineoplastic drugs in China: an interrupted time series study.

Journal: Frontiers in pharmacology

Published: March 13, 2025

Research on strategies for enhancing drug knowledge dissemination on Chinese social media WeChat public accounts based on text mining technology.

Research on strategies for enhancing drug knowledge dissemination on Chinese social media WeChat public accounts based on text mining technology.

Journal: Frontiers in pharmacology

Published: February 02, 2025

Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study.

Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study.

Journal: Frontiers in pharmacology

Published: November 25, 2024

Showing 1-12 of 16

Last Updated: 09/26/2026